These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27138024)

  • 21. Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease.
    Lal C; Strange C
    Expert Opin Pharmacother; 2015 Feb; 16(3):427-34. PubMed ID: 25597386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants.
    Jansat JM; Lamarca R; de Miquel G; Schrödter A; Miletzki B; Gurniak M
    J Clin Pharmacol; 2009 Oct; 49(10):1239-46. PubMed ID: 19592595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device.
    Kosoglou T; Hubbell J; Johnson-Levonas AO; Yunan M; Kantesaria BS; Cutler DL
    Clin Pharmacol Drug Dev; 2014 May; 3(3):222-8. PubMed ID: 27128612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside.
    Cazzola M; Calzetta L; Ora J; Puxeddu E; Rogliani P; Matera MG
    Respir Med; 2015 Oct; 109(10):1305-11. PubMed ID: 26303336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults.
    Maes A; DePetrillo P; Siddiqui S; Reisner C; Dorinsky P
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):223-233. PubMed ID: 29901860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aclidinium bromide combined with formoterol inhibits remodeling parameters in lung epithelial cells through cAMP.
    Lambers C; Costa L; Ying Q; Zhong J; Lardinois D; Dekan G; Schuller E; Roth M
    Pharmacol Res; 2015 Dec; 102():310-8. PubMed ID: 26546746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update.
    D'Urzo AD; Singh D; Donohue JF; Chapman KR; Wise RA
    Expert Rev Respir Med; 2021 Sep; 15(9):1093-1106. PubMed ID: 34137664
    [No Abstract]   [Full Text] [Related]  

  • 28. A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993.
    Mariotti F; Ciurlia G; Spaccapelo L; Muraro A; Acerbi D
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):269-279. PubMed ID: 27209586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.
    Joos GF; Schelfhout VJ; Pauwels RA; Kanniess F; Magnussen H; Lamarca R; Jansat JM; Garcia Gil E
    Respir Med; 2010 Jun; 104(6):865-72. PubMed ID: 20044242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date.
    Moitra S; Bhome AB; Brashier BB
    Drug Des Devel Ther; 2015; 9():1989-99. PubMed ID: 25897208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.
    Lasseter K; Dilzer S; Jansat JM; Garcia Gil E; Caracta CF; Ortiz S
    Pulm Pharmacol Ther; 2012 Apr; 25(2):193-9. PubMed ID: 22366196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany.
    Rivero-Ferrer E; Olesen M; Plana E; Aguado J; Saigí-Morgui N; Rubino A; Daoud SZ; Lei A; Perez-Gutthann S; Schink T; Kristiansen NS; Hallas J; Pottegård A; Rebordosa C
    Clin Drug Investig; 2022 Apr; 42(4):319-331. PubMed ID: 35290649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the efficacy and safety of combined aclidinium bromide and formoterol fumarate in the treatment of chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis.
    Lu H; Huang YT; Chen HJ; Chen PF
    Medicine (Baltimore); 2020 Nov; 99(47):e21856. PubMed ID: 33217787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
    Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
    Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability.
    Doty A; Schroeder J; Vang K; Sommerville M; Taylor M; Flynn B; Lechuga-Ballesteros D; Mack P
    AAPS PharmSciTech; 2018 Feb; 19(2):837-844. PubMed ID: 29019170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects.
    Jansat JM; Lamarca R; Garcia Gil E; Ferrer P
    Int J Clin Pharmacol Ther; 2009 Jul; 47(7):460-8. PubMed ID: 19640353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants.
    Ortiz S; Flach S; Caracta C; Gil EG; Jansat JM
    J Clin Pharmacol; 2012 Jun; 52(6):819-27. PubMed ID: 21628603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review.
    Jones P
    Adv Ther; 2013 Apr; 30(4):354-68. PubMed ID: 23553509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease.
    Matera MG; Sanduzzi A; Cazzola M
    Int J Chron Obstruct Pulmon Dis; 2016; 11():73-9. PubMed ID: 26792987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease.
    Woods JA; Nealy KL; Barrons RW
    Ann Pharmacother; 2013; 47(7-8):1017-28. PubMed ID: 23737515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.